SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR

European Journal of Human Genetics

Volumn 18, Issue 1, 2010, Pages 52-58

  Tiziano, Francesco Danilo ^a   Pinto, Anna Maria ^a   Fiori, Stefania ^a   Lomastro, Rosa ^a   Messina, Sonia ^a,b   Bruno, Claudio ^c   Pini, Antonella ^d   Pane, Marika ^a   D'Amico, Adele ^e   Ghezzo, Alessandro ^d   Bertini, Enrico ^e   Mercuri, Eugenio ^a   Neri, Giovanni ^a   Brahe, Christina ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c G GASLINI INSTITUTE   (Italy)

^d MAGGIORE HOSPITAL   (Italy)

^e BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; SURVIVAL MOTOR NEURON PROTEIN 1; SURVIVAL MOTOR NEURON PROTEIN 2; MESSENGER RNA;

ADULT; ARTICLE; BLOOD; CONTROLLED STUDY; DISEASE SEVERITY; EXON; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SPINAL MUSCULAR ATROPHY; SPLICING DEFECT; CASE CONTROL STUDY; CIRCADIAN RHYTHM; GENE DOSAGE; GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOTE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME;

ADULT; CASE-CONTROL STUDIES; CIRCADIAN RHYTHM; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION; HETEROZYGOTE; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; MUSCULAR ATROPHY, SPINAL; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL OF MOTOR NEURON 2 PROTEIN; TIME FACTORS; YOUNG ADULT;

EID: 77449106557     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2009.116     Document Type: Article

References (31)

1. Zerres K, Rudnik-Schoneborn S, Forrest E et al: A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci 1997; 146: 67-72.
2. LefebvreS,Bü rglen L, Reboullet S et al: Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80: 155-165.
3. Lefebvre S, Burlet P, Liu Q et al: Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 1997; 16: 265-269. (Pubitemid 27280210)
4. Coovert DD, Le TT, McAndrew PE et al: The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet 1997; 6: 1205-1214. (Pubitemid 27351059)
5. Patrizi AL, Tiziano F, Zappata S: SMN protein analysis in fibroblast, amniocyte, and CVS cultures from spinal muscular atrophy patients and its relevance for diagnosis. Eur J Hum Genet 1999; 7: 301-309. (Pubitemid 29213736)
6. Feldkö tter M, Schwarzer V, Wirth R et al: Quantitative analysis of SMN1 and SMN2 based on real-time LightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 2002; 70: 358-368. (Pubitemid 34112291)
7. Tiziano FD, Bertini E, Messina S et al: The Hammersmith functional score correlates with the SMN2 copy number: a multicentric study. Neuromuscul Disord 2007; 17: 400-403. (Pubitemid 46679240)
8. Wirth B, Brichta L, Schrank B et al: Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet 2006; 119: 422-428.
9. Chang J-G, Hsieh-Li H-M, Jong Y-J et al: Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 2001; 98: 9808-9813. (Pubitemid 32769385)
10. Brichta L, Hofmann Y, Hahnen E et al: Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 2003; 12: 2481-2489. (Pubitemid 37220412)
11. Sumner CJ, Huynh TN, Markowitz JA et al: Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 2003; 54: 647-654. (Pubitemid 37346071)
12. Andreassi C, Angelozzi C, Tiziano FD et al: Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 2004; 12: 59-65. (Pubitemid 38180971)
13. Brahe C, Vitali T, Tiziano FD et al: Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet 2005; 13: 256-259. (Pubitemid 40220572)
14. Brichta L, Holker I, Haug K: In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann Neurol 2006; 59: 970-975. (Pubitemid 43830929)
15. Grzeschik SM, Ganta M, Prior TW et al: Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells. Ann Neurol 2005; 58: 194-202. (Pubitemid 41098877)
16. Jarecki J, Chen X, Bernardino A et al: Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Hum Mol Genet 2005; 14: 2003-2018. (Pubitemid 41418036)
17. Angelozzi C, Borgo F, Tiziano FD: Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells. J Med Genet 2008; 45: 29-31. (Pubitemid 351158155)
18. Pane M, Staccioli S, Messina S et al: Daily salbutamol in young patients with SMA type II. Neuromuscul Disord 2008; 18: 536-540.
19. Mercuri E, Bertini E, Messina S et al: Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology 2007; 68: 51-55. (Pubitemid 46058552)
20. Weihl CC, Connolly AM, Pestronk A: Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology 2006; 67: 500-501. (Pubitemid 44214981)
21. Liang WC, Yuo CY, Chang JG et al: The effect of hydroxyurea in spinal muscular atrophy cells and patients. J Neurol Sci 2008; 268: 87-94.
22. Sumner CJ, Kolb SJ, Harmison GG et al: SMN mRNA and protein levels in peripheral blood. Neurology 2006; 66: 1067-1073.
23. Simard LR, Bélanger M-C, Morissette S et al: Preclinical validation of a multiplex real-time assay to quantify SMN mRNA in patients with SMA. Neurology 2007; 68: 451-456. (Pubitemid 46208750)
24. Vezain M, Saugier-Veber P, Melki J et al: A sensitive assay for measuring SMN mRNA levels in peripheral blood and in muscle samples of patients affected with spinal muscular atrophy. Eur J Hum Genet 2007; 15: 1054-1062. (Pubitemid 47491461)
25. Kolb SJ, Gubitz AK, Olszewski Jr RF et al: A novel cell immunoassay to measure survival of motor neurons protein in blood cells. BMC Neurol 2006; 6: 6.
26. Thi Man N, Humphrey E, Lam LT et al: A two-site ELISA can quantify upregulation of SMN protein by drugs for spinal muscular atrophy. Neurology 2008. epub Fpage: ahead Misc: of print.
27. Main M, Kairon H, Mercuri E et al: The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol 2003; 7: 155-159. (Pubitemid 36939996)
28. Gueudin M, Simon F: Plasma RNA viral load in HIV-1 group O infection by real-time PCR. Methods Mol Biol 2005; 304: 221-228.
29. Castelain S, Descamps V, Thibault V et al: TaqMan amplification system with an internal positive control for HCV RNA quantitation. J Clin Virol 2004; 31: 227-234. (Pubitemid 39311803)
30. Tichopad A, Pfaffl MW, Didier A: Tissue-specific expression pattern of bovine prion gene: quantification using real-time RT-PCR. Mol Cell Probes 2003; 17: 5-10. (Pubitemid 36287303)
31. Helmken C, Hofmann Y, Schoenen F et al: Evidence for a modifying pathway in SMA discordant families: reduced SMN level decreases the amount of its interacting partners and Htra2-beta1. Hum Genet 2003; 114: 11-21. (Pubitemid 38165531)